As a 2022 report noted, "obesity remains the most important risk factor for the incidence and progression of osteoarthritis." According to Bliddal, the researchers launched the study to answer this question: "Would a highly effective anti-obesity medication improve KOA to a clinically meaningful degree?" Other studies had tackled the question with inconsistent results, he said
While protein needs vary by body size, activity level, and individual goals, many adults using GLP-1 medications aim for roughly 80 to 120 grams of protein per day to help support muscle maintenance, recovery, and daily energy
If symptoms persist or dietary intake becomes significantly restricted, ask your GP or trial team for a referral to a registered dietitian
Novo Nordisk achieved oral administration by combining semaglutide and SNAC, marking a milestone in the global oral product schedule as the first orally approved GLP-1 receptor agonist in the world